Home   Categories   Grid

Subscribe Now

Cambridge start-up Enhanc3D Genomics wins Johnson & Johnson support for human 3D genome technology

Cambridge start-up Enhanc3D Genomics wins Johnson & Johnson support for human 3D genome technology

Cambridge start-up Enhanc3D Genomics wins Johnson & Johnson support for human 3D genome technology

03 June 2022

Platform could aid precision medicine.


‘I had no confidence of success’ says Wellcome Sanger Institute director and cancer genetics pioneer Prof Sir Mike Stratton

‘I had no confidence of success’ says Wellcome Sanger Institute director and cancer genetics pioneer Prof Sir Mike Stratton

‘I had no confidence of success’ says Wellcome Sanger Institute director and cancer genetics pioneer Prof Sir Mike Stratton

03 June 2022

An exclusive in-depth interview with the winner of our inaugural Lifetime Achievement Award.


NRG Therapeutics’ £2.68m award will help fund new hope against Parkinson’s disease

NRG Therapeutics’ £2.68m award will help fund new hope against Parkinson’s disease

NRG Therapeutics’ £2.68m award will help fund new hope against Parkinson’s disease

02 June 2022

It will fund the clinical development of its brain-penetrating small molecule inhibitors.

2

AstraZeneca CEO Pascal Soriot is knighted after leadership during pandemic

AstraZeneca CEO Pascal Soriot is knighted after leadership during pandemic

AstraZeneca CEO Pascal Soriot is knighted after leadership during pandemic

01 June 2022

He is honoured in the Queen’s Jubilee Birthday Honours 2022.


Bicycle Therapeutics opens new headquarters on Granta Park

Bicycle Therapeutics opens new headquarters on Granta Park

Bicycle Therapeutics opens new headquarters on Granta Park

27 May 2022

Sir Greg Winter among speakers as Portway Building premises team looks to accelerate development of synthesised medicines


In pictures: King and queen of Sweden tour AstraZeneca’s Discovery Centre on visit to Cambridge

In pictures: King and queen of Sweden tour AstraZeneca’s Discovery Centre on visit to Cambridge

In pictures: King and queen of Sweden tour AstraZeneca’s Discovery Centre on visit to Cambridge

26 May 2022

King Carl XVI Gustaf and Queen Silvia were given an insight into the company’s cutting-edge R&D technology.


Avacta completes move away from Whittlesford to White City

Avacta completes move away from Whittlesford to White City

Avacta completes move away from Whittlesford to White City

18 May 2022

The company has brought its R&D teams together in London.


AstraZeneca revenues rise 60% to $11bn in first quarter as it unveils plans for new Alexion headquarters

AstraZeneca revenues rise 60% to $11bn in first quarter as it unveils plans for new Alexion headquarters

AstraZeneca revenues rise 60% to $11bn in first quarter as it unveils plans for new Alexion headquarters

04 May 2022

Meanwhile, it expects sales of its Covid-19 vaccine to decline in 2022.


Dengue threat to be tackled using AI-powered drug discovery as BenevolentAI teams up with DNDi

Dengue threat to be tackled using AI-powered drug discovery as BenevolentAI teams up with DNDi

Dengue threat to be tackled using AI-powered drug discovery as BenevolentAI teams up with DNDi

28 April 2022

There are an estimated 390 million infections each year.


Spanish medical imaging specialist Quibim heads to Cambridge after support

Spanish medical imaging specialist Quibim heads to Cambridge after support

Spanish medical imaging specialist Quibim heads to Cambridge after support

22 April 2022

Growth Works and Eastern AHSN helped the company as it scales.


Mursla’s nanochip technology for exosome detection poised to transform disease diagnosis

Mursla’s nanochip technology for exosome detection poised to transform disease diagnosis

Mursla’s nanochip technology for exosome detection poised to transform disease diagnosis

21 April 2022

The Cambridge Science Park company is also working with Roche Diagnostics on a liver cancer pilot study.


Avacta achieves AffyXell joint venture milestone, triggering increased equity stake

Avacta achieves AffyXell joint venture milestone, triggering increased equity stake

Avacta achieves AffyXell joint venture milestone, triggering increased equity stake

20 April 2022

It has developed and characterised Affimer proteins against the first target for AffyXell.


How Adrestia Therapeutics is pioneering synthetic rescue

How Adrestia Therapeutics is pioneering synthetic rescue

How Adrestia Therapeutics is pioneering synthetic rescue

14 April 2022

An interview with Prof Steve Jackson and CEO Robert Johnson


Axol Bioscience raises further £3.2m to extend iPSC products for drug discovery market

Axol Bioscience raises further £3.2m to extend iPSC products for drug discovery market

Axol Bioscience raises further £3.2m to extend iPSC products for drug discovery market

13 April 2022

It extends the total raised to £7m.


BiologIC’s biocomputer invention to be used by Oxford Biomedica to develop viral vectors for cancer therapies

BiologIC’s biocomputer invention to be used by Oxford Biomedica to develop viral vectors for cancer therapies

BiologIC’s biocomputer invention to be used by Oxford Biomedica to develop viral vectors for cancer therapies

31 March 2022

The Cambridge biotech wants to ‘drive a revolution in biology’.


Sosei Heptares confirms new leadership focused on driving growth from its Granta Park R&D centre

Sosei Heptares confirms new leadership focused on driving growth from its Granta Park R&D centre

Sosei Heptares confirms new leadership focused on driving growth from its Granta Park R&D centre

31 March 2022

New CEO and new head of UK R&D confirmed.


Drug identified by BenevolentAI shown to reduce deaths in patients hospitalised by Covid-19

Drug identified by BenevolentAI shown to reduce deaths in patients hospitalised by Covid-19

Drug identified by BenevolentAI shown to reduce deaths in patients hospitalised by Covid-19

10 March 2022

Results have been published from the University of Oxford RECOVERY trial.


Adrestia Therapeutics appoints first full-time CEO as it builds synthetic rescue therapy platform

Adrestia Therapeutics appoints first full-time CEO as it builds synthetic rescue therapy platform

Adrestia Therapeutics appoints first full-time CEO as it builds synthetic rescue therapy platform

10 March 2022

Robert Johnson previously co-founded Boston-based gene therapy company Affinia Therapeutics.


University of Cambridge spin-out DIOSynVax to receive $42m to develop universal coronavirus vaccine

University of Cambridge spin-out DIOSynVax to receive $42m to develop universal coronavirus vaccine

University of Cambridge spin-out DIOSynVax to receive $42m to develop universal coronavirus vaccine

08 March 2022

Prime Minister Boris Johnson announce the funding at the Global Pandemic Preparedness Summit.


Stem cell discovery at Babraham Institute creates opportunity to study our genomic wake-up call

Stem cell discovery at Babraham Institute creates opportunity to study our genomic wake-up call

Stem cell discovery at Babraham Institute creates opportunity to study our genomic wake-up call

04 March 2022

The discovery could help us explore the earliest events in our development.


This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More